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Summary 
Synucleins are small, soluble proteins expressed primarily in neural tissue and in certain tumors. The
family includes three known proteins: -synuclein, -synuclein, and -synuclein. All synucleins have in
common a highly conserved -helical lipid-binding motif with similarity to the class-A2 lipid-binding
domains of the exchangeable apolipoproteins. Synuclein family members are not found outside
vertebrates, although they have some conserved structural similarity with plant ‘late-embryo-
abundant’ proteins. The - and -synuclein proteins are found primarily in brain tissue, where they are
seen mainly in presynaptic terminals. The -synuclein protein is found primarily in the peripheral
nervous system and retina, but its expression in breast tumors is a marker for tumor progression.
Normal cellular functions have not been determined for any of the synuclein proteins, although some
data suggest a role in the regulation of membrane stability and/or turnover. Mutations in -synuclein
are associated with rare familial cases of early-onset Parkinson’s disease, and the protein accumulates
abnormally in Parkinson’s disease, Alzheimer’s disease, and several other neurodegenerative illnesses.
The current challenge is to understand the normal cellular function of these proteins and how they
might contribute to the development of human disease.
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Gene organization and evolutionary history 
The synuclein family consists of three distinct genes, -synu-
clein, -synuclein, and -synuclein, which have so far been
described only in vertebrates. Table 1 catalogs the unique
members of the synuclein family that are currently listed in
GenBank [1]; these 16 sequences encode the orthologs of each
of the three synucleins in the species in which they have been
described. The sequences are shown aligned in Figure 1a and
their estimated relationships are indicated by the dendro-
gram in Figure 1b. The -synuclein gene has been mapped to
human chromosome 4q21.3-q22 [2], -synuclein to human
chromosome 5q35 [3], and -synuclein to human chromo-
some 10q23.2-q23.3 [4]. The -synuclein gene is organized
as 7 exons, 5 of which are protein-coding, while the -synu-
clein gene has 6 exons (5 protein-coding) and the -synuclein
gene has 5 exons (all protein-coding) (reviewed in [5]).
Characteristic structural features
All synuclein protein sequences consist of a highly conserved
amino-terminal domain that includes a variable number of
11-residue repeats and a less-conserved carboxy-terminal
domain that includes a preponderance of acidic residues.
The only significant divergences within the repeat domain
are the deletion of 11 amino acids (residues 53-63) in all
-synucleins and the addition of a repeat after residue 32 in
the -synuclein of the electric ray Torpedo californica
(Figure 1a). The 11-mer repeats make up a conserved
apolipoprotein-like class-A2 helix (Figure 2a,b), which medi-
ates binding to phospholipid vesicles; lipid binding is accom-
panied by a large shift in protein secondary structure, from
around 3% to over 70% -helix [6]. 
Although no confirmed synuclein orthologs have been iden-
tified in non-vertebrates, a low-scoring BLAST ‘hit’ for simi-
larity is obtained for LEA76, a plant protein belonging to the
late embryo-abundant (LEA) group III protein family. Upon
further examination, the sequence similarity is attributable
to the presence of an 11-residue repeat encoding a similar
class-A2 lipid-binding motif (Figure 2c). Like synucleins,
LEA group III proteins are relatively unordered in solution;
upon fast drying, however, they shift to a largely -helical
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conformation [7], and are hypothesized to associate with and
stabilize cellular membranes against desiccation stress. A
Caenorhabditis elegans LEA homolog has been reported [8]
that also shares this structural motif (Figure 2d). Thus,
despite the low degree of primary sequence similarity,
further scrutiny of the LEA proteins’ potential functional
relationships to the synucleins is warranted.
Localization and function
The first synuclein was identified in 1988 by Maroteaux et al.
[9], who screened an expression library with an antiserum
raised against purified cholinergic vesicles from the electric
organ of the Pacific electric ray Torpedo californica. This
initial cDNA clone (encoding electric-ray -synuclein;
Table 1) was used to isolate a rat clone encoding a 140-
amino-acid protein (rat -synuclein, Table 1). The product of
the -synuclein gene was first isolated as a bovine brain-
specific phosphoprotein (phosphoneuroprotein 14 kDa or
PNP14), and its sequence was first described in 1993 [10]. 
The - and -synuclein proteins are predominately
expressed in brain, particularly in the neocortex, hippocam-
pus, striatum, thalamus, and cerebellum; protein
immunoreactivity is enriched at presynaptic terminals
[11,12]. Although their normal physiological functions are
unknown, several lines of evidence suggest a role in mem-
brane-associated processes at the presynaptic terminal:
-synuclein is specifically upregulated in a discrete popula-
tion of presynaptic terminals of the songbird brain during a
period of song-acquisition-related synaptic rearrangement
[13]; - and -synuclein proteins were biochemically
purified from bovine brain as constitutive inhibitors of phos-
pholipase D2 [14], an enzyme that catalyzes the hydrolysis of
phosphatidylcholine to phosphatidic acid and appears to
play a role in cytoskeletal reorganization and/or endocytosis
at the plasma membrane [15]; -synuclein knockout mice
have enhanced dopamine release at nigrostriatal terminals
in response to paired electrical stimuli, suggesting that
-synuclein is an activity-dependent negative regulator of
dopamine neurotransmission [16]; and, finally, depletion of
-synuclein from cultured primary hippocampal neurons by
treatment with antisense oligonucleotides results in a
decrease in the distal pool of presynaptic vesicles, as visual-
ized by electron microscopy [17]. 
Mammalian -synuclein was first identified as breast cancer-
specific gene 1 (BCSG1) in a high-throughput direct differen-
tial-cDNA-sequencing screen for markers of breast cancer
[18]. The protein is expressed in the peripheral nervous
system (in primary sensory neurons, sympathetic neurons,
and motor neurons) [18] and is also detected in brain [19],
ovarian tumors [20], and in the olfactory epithelium [21]. A
sequence dubbed synoretin was independently isolated from
ocular tissues in a screen for novel proteins regulating pho-
totransduction and is now thought to represent the bovine
ortholog of -synuclein [22]. The normal cellular function of
-synuclein is likewise unknown, but exogenous expression
of the protein increases the invasive and metastatic potential
of breast tumors [23].
Synucleins in neurodegenerative disease
In 1993, Ueda et al. reported [24] that a short peptide (non-
amyloid component, NAC) derived from purified amyloid
Table 1 
Summary of known synuclein family members
Gene type Species Other names OMIM accession number* GenBank accession number†
 Human NACP 163890 586087
 Rat SYN1, SYN2, SYN3 (splice variants) 9507125
 Mouse SYN2 (splice variant) 6678047
 Chicken 7689260
 Canary Synelfin 2501104
 Human 602569 4507111
 Bovine PNP14 464424
 Rat PNP14 2501106
 Mouse 15809030
 Chicken 7689264
 Human BCSG1, persyn 602998 4507113
 Rat Sensory neuron synuclein 13928954
 Mouse Persyn 6755592
 Chicken Persyn 7689262
 Bovine Synoretin 6942174
 Electric ray Synuclein 730882
*See OMIM [36]; †see GenBank [1]. 
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plaques from the brains of people with Alzheimer’s disease
was derived from a larger precursor protein, non-amyloid
component precursor (NACP), which is now known to be
identical to human -synuclein. Then, in 1997, Poly-
meropoulos and colleagues reported [25] that a missense
mutation (A53T) in -synuclein was genetically linked to
early-onset, familial Parkinson’s disease. Description of a
second linked mutation (A30P) followed in 1998 [26]. Anti-
bodies to -synuclein protein were used to show that the
protein accumulates in the ubiquitinated protein inclusions
and dystrophic neurites (Lewy bodies and Lewy neurites) that
are the hallmark pathological features of the disease; this
localization was observed even in cases of sporadic Parkin-
son’s disease, which are not associated with -synuclein muta-
tions [27]. Indeed, -synuclein is the primary fibrillar
component of Lewy bodies, and -synuclein lesions are also
observed in cases of dementia with Lewy bodies and multiple
system atrophy, and in some cases of Alzheimer’s disease, the
parkinsonism-dementia complex of Guam, and Hallervorden-
Spatz disease (reviewed in [28]). Although the accumulation
of fibrillar -synuclein in neurodegenerative disease can be
interpreted as evidence that the fibrils are themselves toxic, an
equally plausible view is that the fibrils are inert or even pro-
tective. Conway et al. [29] recently observed that the neuro-
transmitter dopamine forms adducts with -synuclein that
stabilize a protofibrillar form of the protein (at the expense of
fibril formation); the authors proposed that the accumulation
of toxic -synuclein protofibrils could account for the selective
loss of dopamine-containing neurons in Parkinson’s disease.
The detection of -synuclein in ubiquitinated inclusions
raises the issue of whether -synuclein is normally targeted
for turnover by the ubiquitin-proteasome machinery. Although
the evidence for -synuclein turnover by the proteasome is
equivocal [30-32], proteasomal inhibitors do not appear to
cause accumulation of poly-ubiquitinated -synuclein. The
-synuclein binding partner synphilin-1 was, however,
recently shown to be ubiquitinated and targeted for protea-
somal turnover by parkin, a ubiquitin ligase, mutation of
which is itself a risk factor for familial Parkinson’s disease.
This may provide a common pathological mechanism
linking familial mutations in -synuclein and parkin via
their common interactions with synphilin-1 [33]. 
The - and -synuclein proteins are not found in Lewy
bodies, but both are associated with hippocampal axon
pathology in Parkinson’s disease and dementia with Lewy
bodies [34]. A change in the expression of -synuclein has
also been specifically observed in the retina of patients with
Alzheimer’s disease [22].
Figure 1
Alignment and relationships of the 16 known synuclein sequences. There are about 80 synuclein sequences in GenBank [1], which can be further sorted
into 16 unique groups, each representing a single protein-coding sequence orthologous to one of the three synucleins (summarized in Table 1). (a) The
resulting 16 synuclein sequences were aligned with the Multalin program [37]. Shading indicates identity with rat -synuclein;  blue bars represent the 
11-residue repeats. (b) A dendrogram of synuclein relationships, generated with ClustalW [38] and displayed using TreeView [39].
  Rat               MDVFMKGLSKAKEGVVAAAEKTKQGVAEAA-----------GKTKEGVLYVGSKTKEGVVHGVTTVAEKTKEQVTNVGGA
  Mouse             MDVFMKGLSKAKEGVVAAAEKTKQGVAEAA-----------GKTKEGVLYVGSKTKEGVVHGVTTVAEKTKEQVTNVGGA
  Human             MDVFMKGLSKAKEGVVAAAEKTKQGVAEAA-----------GKTKEGVLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGA
  Chicken           MDVFMKGLNKAKEGVVAAAEKTKQGVAEAA-----------GKTKEGVLYVGSRTKEGVVHGVTTVAEKTKEQVSNVGGA
  Canary            MDVFMKGLSKAKEGVVAAAEKTKQGVAEAA-----------GKTKEGVLYVGSRTKEGVVHGVTTVAEKTKEQVSNVGGA
  Rat               MDVFMKGLSMAKEGVVAAAEKTKQGVTEAA-----------EKTKEGVLYVGSKTKEGVVQGVASVAEKTKEQASHLGGA
  Mouse             MDVFMKGLSMAKEGVVAAAEKTKQGVTEAA-----------EKTKEGVLYVGSKT-SGVVQGVASVAEKTKEQASHLGGA
  Human             MDVFMKGLSMAKEGVVAAAEKTKQGVTEAA-----------EKTKEGVLYVGSKTREGVVQGVASVAEKTKEQASHLGGA
  Bovine            MDVFMKGLSMAKEGVVAAAEKTKQGVTEAA-----------EKTKEGVLYVGSKTKEGVVQGVASVAEKTKEQASHLGGA
  Chicken           MEVFMKGLSKAKEGVVAAAEKTKQGVAEAA-----------EKTKEGVLYVGSKT-QGVVQGVTSVAEKAKEQASQLGEA
  Bovine            MDVFKKGFSIAKEGVVGAVEKTKQGVTEAA-----------EKTKEGVMYVGAKTKEGVVQSVTSVAEKTKEQANAVSEA
  Human             MDVFKKGFSIAKEGVVGAVEKTKQGVTEAA-----------EKTKEGVMYVGAKTKENVVQSVTSVAEKTKEQANAVSEA
  Rat               MDVFKKGFSIAREGVVGAVEKTTQGVTEAA-----------EKTKEGVMYVGAKTKGERGTSVTSVAEKTKEQANAVSEA
  Mouse             MDVFKKGFSIAKEGVVGAVEKTKQGVTEAA-----------EKTKEGVMYVGTKTKENVVQSVTSVAEKTKEQANAVSEA
  Chicken           MDVFKKGFSIAKEGVVAAAEKTKQGVTEAA-----------EKTKEGVMYVGTKTKEGVVQSVTSVAEKTKEQANVVGEA
  Electric ray      MDVLKKGFSFAKEGVVAAAEKTKQGVQDAAEKTKQGVQDAAEKTKEGVMYVGTKTKEGVVQSVNTVTEKTKEQANVVGGA
  Rat               VVTGVTAVAQKTVEGAGNIAAATGFVKKDQMGK--GEEGYPQEGILE---DMPVDPSSEAYEMPSEEGYQDYEPEA
  Mouse             VVTGVTAVAQKTVEGAGNIAAATGFVKKDQMGK--GEEGYPQEGILE---DMPVDPGSEAYEMPSEEGYQDYEPEA
  Human             VVTGVTAVAQKTVEGAGSIAAATGFVKKDQLGK--NEEGAPQEGILE---DMPVDPDNEAYEMPSEEGYQDYEPEA
  Chicken           VVTGVTAVAQKTVEGAGNIAAATGLVKKDQLAKQ-NEEGFLQEGMVNN-TDIPVDPENEAYEMPPEEEYQDYEPEA
  Canary            VVTGVTAVAQKTVEGAGNIAAATGLVKKDQLAKQ-NEEGFLQEGMVNN-TGAAVDPDNEAYEMPPEEEYQDYEPEA
  Rat               VFS-----------GAGNIAAATGLVKKEEFPTDLKPEEVAQEAAEEPLIEPLMEPEGESYEDSPQEEYQEYEPEAKGP
  Mouse             VFS-----------GAGNIAAATGLVKKEEFPTDLKPEEVAQEAAEEPLIEPLMEPEGESYEDSPQEEYQEYEPEA
  Human             VFS-----------GAGNIAAATGLVKREEFPTDLKPEEVAQEAAEEPLIEPLMEPEGESYEDPPQEEYQEYEPEA
  Bovine            VFS-----------GAGNIAAATGLVKKEEFPTDLKPEEVAQEAAEEPLIEPLMEPEGESYEEQPQEEYQEYEPEA
  Chicken           AFS-----------GAGNIAAATGLVKKEEFPADLKAEEVAQEAVEEPLVEPLLEPEGESYEESPQEEYQEYEPEA
  Bovine            VVSSVNTVATKTVEEVENIAVTSGVVHKEALKQPVPSQED--------------EAAKA-EEQVAEETKSGGD
  Human             VVSSVNTVATKTVEEAENIAVTSGVVRKEDLRPSAPQQEG--------------VASKE-KEEVAEEAQSGGD
  Rat               VVSSVNTVATETVEEAENIVVTTGVVRKEDLEPPAQDQE-----------------AKE-QEE-GEEAKSGGD
  Mouse             VVSSVNTVANKTVEEAENIVVTTGVVRKEDLEPPAQDQE-----------------AKE-QEE-NEEAKSGED
  Chicken           VVASVNTVANKTVEGAETIVATTGVVKKEDLAPQQPAAEG--------------EAAIPGSTEGGGEGENEGN
  Electric ray      VVAGVNTVASKTVEGVENVAAASGVVKLDEHGREIPAEQV--------------AEGKQTTQEPLVEATEATEETGK
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The association of synucleins with human disease has focused
a great deal of interest on this protein family. The question of
what the synucleins do still remains, however. Most of the
experimental evidence available with regard to function is
gleaned from experiments with -synuclein, but the conser-
vation of an extended, class-A2 amphipathic  helix compris-
ing more than half of each of the protein sequences indicates
a common biochemical mechanism among all synucleins,
probably involving lipid binding. Perrin et al. [35] report irre-
versible multimerization of -, -, and -synuclein upon
exposure to polyunsaturated phospholipid species, cellular
membrane components that are the most susceptible to
oxidative damage. This specific interaction might serve to
protect these vulnerable lipids from damage or to scavenge
damaged lipids and target them for turnover. Paxinou et al.
[32] also noted recently that -synuclein is degraded, at least
in part, by the lysosome, suggesting a role for -synuclein in
the autophagocytic clearance of damaged cellular organelles.
Thus, it is tempting to speculate that the synucleins help to
maintain cellular membrane integrity. But much work
remains to be done to elucidate the normal cellular functions
of these unusually conserved proteins and to determine how
they contribute to diverse disease processes spanning neuro-
degenerative disease and cancer.
Acknowledgements
The author is supported by NIH grant 1RO1 AG13762 from the National
Institute on Aging.
Additional data files
Additional data files available with the online version of this
article include animated versions of Figure 2a, Figure 2b,
Figure 2c and Figure 2d, which can be viewed with Quick-
Time Player. 
References
1. Searching GenBank
[http://www.ncbi.nlm.nih.gov/Genbank/GenbankSearch.html] 
An annotated sequence database maintained by the National Institutes
of Health.
2. Chen X, de Silva HA, Pettenati MJ, Rao PN, St George-Hyslop P,
Roses AD, Xia Y, Horsburgh K, Ueda K, Saitoh T: The human
NACP/alpha-synuclein gene: chromosome assignment to
4q21.3-q22 and TaqI RFLP analysis. Genomics 1995, 26:425-427.
Chromosomal mapping of the -synuclein gene.
3. Spillantini MG, Divane A, Goedert M: Assignment of human
alpha-synuclein (SNCA) and beta-synuclein (SNCB) genes
to chromosomes 4q21 and 5q35. Genomics 1995, 27:379-381. 
Chromosomal mapping of the - and -synuclein genes.
4. Ninkina NN, Alimova-Kost MV, Paterson JW, Delaney L, Cohen BB,
Imreh S, Gnuchev NV, Davies AM, Buchman VL: Organization,
expression and polymorphism of the human persyn gene.
Hum Mol Genet 1998, 7:1417-1424. 
Chromosomal mapping of the -synuclein gene.
5. Lavedan C: The synuclein family. Genome Res 1998, 8:871-880.  
A review of the common properties of the synuclein protein family,
including gene organization, tissue distribution, and the relationship of
protein family members to human disease.
6. Perrin RJ, Woods WS, Clayton DF, George JM: Interaction of
human alpha-synuclein and Parkinson’s disease variants
with phospholipids. Structural analysis using site-directed
mutagenesis. J Biol Chem 2000, 275:34393-34398. 
The -helical lipid-binding domain of -synuclein was mapped to exons
3, 4, and 5 using site directed mutagenesis.
7. Wolkers WF, McCready S, Brandt WF, Lindsey GG, Hoekstra FA:
Isolation and characterization of a D-7 LEA protein from
pollen that stabilizes glasses in vitro. Biochim Biophys Acta 2001,
1544:196-206. 
The authors describe a shift in secondary structure from random coil
to  helix by a plant LEA protein upon fast drying of the protein. The
shift is thought to contribute to stabilization of the dehydrating cyto-
plasm.  
8. Entrez Nucleotide entry for Caenorhabditis elegans LEA
[http://www.ncbi.nlm.nih.gov/entrez/viewer.cgi?val=AF016513.1]
A C. elegans sequence with homology to plant late embryo abundant
(LEA) proteins.
4 Genome Biology Vol 3 No 1 George
Figure 2
Comparison of the amphipathic -helical domains of -synuclein and
related proteins. Sequences of interest were imported into Swiss-
PdbViewer [40], assigned an ideal -helical structure, and exported as
.pdb files. Models were then formatted and exported with RASMol [41],
and animations (available with the complete version of this article, online)
were compiled with QuickTime Pro. (a) Human -synuclein residues
1-50, modeled as an -helix. The initial frame shown here shows just the
hydrophilic face of the helix, with acidic residues confined to the center
(red) and basic residues at each interface (yellow); the opposite
hydrophobic face (shown in the animation online) contains only uncharged
residues (white). (b) Human apolipoprotein AI residues 190-231;
(c) Arabidopsis thaliana LEA76 residues 1-50; (d) C. elegans LEA residues
351-400; all are modeled as in (a).
9. Maroteaux L, Campanelli JT, Scheller RH: Synuclein: a neuron-
specific protein localized to the nucleus and presynaptic
nerve terminal. J Neurosci 1988, 8:2804-2815. 
The first synuclein family member was identified in the Pacific electric
ray Torpedo californica.
10. Nakajo S, Tsukada K, Omata K, Nakamura Y, Nakaya K: A new
brain-specific 14-kDa protein is a phosphoprotein. Its
complete amino acid sequence and evidence for phosphory-
lation. Eur J Biochem 1993, 217:1057-1063. 
The first -synuclein was directly isolated from bovine brain.
11. Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel
A, Saitoh T: The precursor protein of non-A beta component
of Alzheimer’s disease amyloid is a presynaptic protein of
the central nervous system. Neuron 1995, 14:467-475. 
This study maps the distribution of -synuclein protein in rat brain and
demonstrates localization to presynaptic terminals.
12. Nakajo S, Shioda S, Nakai Y, Nakaya K: Localization of phospho-
neuroprotein 14 (PNP 14) and its mRNA expression in rat
brain determined by immunocytochemistry and in situ
hybridization. Brain Res Mol Brain Res 1994, 27:81-86. 
The authors map the distribution of -synuclein protein and mRNA in
rat brain.
13. George JM, Jin H, Woods WS, Clayton DF: Characterization of a
novel protein regulated during the critical period for song
learning in the zebra finch. Neuron 1995, 15:361-372. 
Zebra finch -synuclein protein is transiently expressed in a brain area
associated with song acquisition during the critical period for song
learning; expression declines concomitantly with song stabilization.
14. Jenco JM, Rawlingson A, Daniels B, Morris AJ: Regulation of phos-
pholipase D2: selective inhibition of mammalian phospholi-
pase D isoenzymes by alpha- and beta-synucleins. Biochemistry
1998, 37:4901-4909. 
The activity of phospholipase D2 (PLD2) is thought to be constitutively
repressed in vivo. Purification of an endogenous inhibitor of PLD2
yielded - and -synuclein proteins.
15. Colley WC, Sung TC, Roll R, Jenco J, Hammond SM, Altshuller Y,
Bar-Sagi D, Morris AJ, Frohman MA: Phospholipase D2, a distinct
phospholipase D isoform with novel regulatory properties
that provokes cytoskeletal reorganization. Curr Biol 1997,
7:191-201. 
Summarizes the enzymatic activity and potential physiological roles of
PLD2.
16. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH,
Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, et al.: Mice
lacking alpha-synuclein display functional deficits in the
nigrostriatal dopamine system. Neuron 2000, 25:239-252. 
Electrophysiological characterization of -synuclein null mice demon-
strates altered dopamine release and a reduction in striatal dopamine.
17. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM: Synucleins are
developmentally expressed, and alpha-synuclein regulates
the size of the presynaptic vesicular pool in primary hip-
pocampal neurons. J Neurosci 2000, 20:3214-3220. 
Antisense depletion of -synuclein from cultured primary hippocampal
neurons causes a decline in a discrete population of presynaptic vesicles.
18. Ji H, Liu YE, Jia T, Wang M, Liu J, Xiao G, Joseph BK, Rosen C, Shi
YE: Identification of a breast cancer-specific gene, BCSG1, by
direct differential cDNA sequencing. Cancer Res 1997, 57:759-
764.
The first mammalian member of the -synuclein subfamily, breast-
cancer-specific gene 1 (BCSG1), was identified in a screen for markers
of breast cancer.
19. Buchman VL, Adu J, Pinon LG, Ninkina NN, Davies AM: Persyn, a
member of the synuclein family, has a distinct pattern of
expression in the developing nervous system. J Neurosci 1998,
18:9335-9341. 
Mapping of the expression of -synuclein protein within the brain and
peripheral nervous system.
20. Lavedan C, Leroy E, Dehejia A, Buchholtz S, Dutra A, Nussbaum RL,
Polymeropoulos MH: Identification, localization and charac-
terization of the human gamma-synuclein gene. Hum Genet
1998, 103:106-112. 
Reports the organization and chromosomal location of the -synuclein
gene and also maps the tissue distribution of the protein.
21. Duda JE, Shah U, Arnold SE, Lee VM, Trojanowski JQ: The expres-
sion of alpha-, beta-, and gamma-synucleins in olfactory
mucosa from patients with and without neurodegenerative
diseases. Exp Neurol 1999, 160:515-522.
Documentation of the expression of -synuclein protein in the olfac-
tory epithelium.
22. Surguchov A, McMahan B, Masliah E, Surgucheva I: Synucleins in
ocular tissues. J Neurosci Res 2001, 65:68-77. 
Mapping of the distributions of -, -, and -synuclein proteins in retina
and optic nerve.
23. Jia T, Liu YE, Liu J, Shi YE: Stimulation of breast cancer invasion
and metastasis by synuclein gamma. Cancer Res 1999, 59:742-747.
Demonstrates that overexpression of -synuclein in breast-cancer cells
increases motility and invasiveness in vitro and metastatic potential in vivo.
24. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M,
Otero DA, Kondo J, Ihara Y, Saitoh T: Molecular cloning of
cDNA encoding an unrecognized component of amyloid
in Alzheimer disease. Proc Natl Acad Sci USA 1993, 90:11282-
11286. 
A fragment of -synuclein was isolated from plaque material from
patients with Alzheimer’s disease. This is the first report of an associa-
tion of -synuclein with neurodegenerative disease.
25. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra
A, Pike B, Root H, Rubenstein J, Boyer R, et al.: Mutation in the
alpha-synuclein gene identified in families with Parkinson’s
disease. Science 1997, 276:2045-2047. 
Identification of the first -synuclein mutation linked to familial early-
onset Parkinson’s disease.
26. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S,
Przuntek H, Epplen JT, Schols L, Riess O: Ala30Pro mutation in
the gene encoding alpha-synuclein in Parkinson’s disease.
Nat Genet 1998, 18:106-108.
Description of the second -synuclein mutation linked to Parkinson’s
disease.
27. Irizarry MC, Growdon W, Gomez-Isla T, Newell K, George JM,
Clayton DF, Hyman BT: Nigral and cortical Lewy bodies and
dystrophic nigral neurites in Parkinson’s disease and cortical
Lewy body disease contain alpha-synuclein immunoreactiv-
ity. J Neuropathol Exp Neurol 1998, 57:334-337. 
Identification of -synuclein as an excellent immunological marker for
Lewy bodies and Lewy neurites.
28. Goedert M: Alpha-synuclein and neurodegenerative diseases.
Nat Rev Neurosci 2001, 2:492-501. 
A comprehensive review of the relationship between -synuclein accu-
mulation and human neurodegenerative disease.
29. Conway KA, Rochet JC, Bieganski RM, Lansbury PT: Kinetic stabi-
lization of the -synuclein protofibril by a dopamine--synu-
clein adduct. Science 2001, 294:1346-1349. 
A screen for compounds inhibiting -synuclein fibrilization yielded pri-
marily catecholamines related to dopamine.
30. Bennett MC, Bishop JF, Leng Y, Chock PB, Chase TN, Mouradian
MM: Degradation of alpha-synuclein by proteasome. J Biol
Chem 1999, 274:33855-33858. 
The authors report that A53T -synuclein has a longer half-life than
wild-type -synuclein in transfected SY5Y cells. Turnover of both iso-
forms was blocked by the selective proteasomal inhibitor beta-
lactone.
31. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trocken-
bacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ: Ubiquitina-
tion of a new form of alpha-synuclein by parkin from human
brain: implications for Parkinson’s disease. Science 2001,
293:263-269. 
This paper reports the identification of a novel O-glycosylated form of
-synuclein (alphaSp22), which is a target for ubiquitination by parkin,
an E3 ubiquitin ligase implicated in Parkinson’s disease.
32. Paxinou E, Chen Q, Weisse M, Giasson BI, Norris EH, Rueter SM,
Trojanowski JQ, Lee VM, Ischiropoulos H: Induction of alpha-
synuclein aggregation by intracellular nitrative insult. J
Neurosci 2001, 21:8053-8061. 
The authors conclude that inhibition of the proteasome in HEK-293
cells does not alter the steady-state levels of transfected -synuclein.
33. Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J, Ross CA,
Dawson VL, Dawson TM: Parkin ubiquitinates the alpha-synu-
clein-interacting protein, synphilin-1: implications for Lewy-
body formation in Parkinson disease. Nat Med 2001,
7:1144-1150. 
Demonstrates ubiquitination of the -synuclein-associated protein syn-
philin by the E3 ubiquitin ligase parkin, and shows that mutations in
co
m
m
ent
review
s
repo
rts
depo
sited research
interactio
ns
info
rm
atio
n
refereed research
http://genomebiology.com/2001/3/1/reviews/3002.5
parkin that are linked to Parkinson’s disease disrupt its ability to ubiqui-
tinate synphilin.
34. Galvin JE, Uryu K, Lee VM, Trojanowski JQ: Axon pathology in
Parkinson’s disease and Lewy body dementia hippocampus
contains alpha-, beta-, and gamma-synuclein. Proc Natl Acad Sci
USA 1999, 96:13450-13455. 
The authors report that - and -synuclein, although not found in Lewy
bodies, are associated with hippocampal axon pathology in both
Parkinson’s disease and dementia with Lewy bodies.
35. Perrin RJ, Woods WS, Clayton DF, George JM: Exposure to long-
chain polyunsaturated fatty acids triggers rapid multimer-
ization of synucleins. J Biol Chem 2001, 276:41958-41962. 
This paper reports rapid and irreversible multimerization of each of the
synuclein family members when exposed to very long-chain polyunsat-
urated fatty acids such as the second-messenger arachidonic acid.
36. Online Mendelian Inheritance in Man (OMIM)
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM]
A catalog of human genes and genetic disorders at the National Center
for Biotechnology Information.
37. Corpet F: Multiple sequence alignment with hierarchical clus-
tering. Nucleic Acids Res 1988, 16:10881-10890.
The Multalin program is useful for creating multiple alignments and for-
matting them for display.
38. Thompson J, Higgins D, Gibson T: CLUSTAL W: improving the
sensitivity of progressive multiple sequence alignment
through sequence weighting, position-specific gap penalties
and weight matrix choice. Nucleic Acids Res 1994, 22:4673-4680. 
This program calculates the optimal alignment between multiple
sequences; output can be as a multiple alignment or as a phylogenetic
tree.
39. Page RD: TreeView: an application to display phylogenetic
trees on personal computers. Comput Appl Biosci 1996, 12:357-
358.
This application is useful for displaying the output of ClustalW.
40. Guex N, Peitsch MC: SWISS-MODEL and the Swiss-Pdb-
Viewer: an environment for comparative protein modeling.
Electrophoresis 1997, 18:2714-2723. 
This program can be used to render molecular coordinates into three-
dimensional images; it can also be used to assign an idealized secondary
structure to a sequence and then generate the corresponding molecu-
lar coordinates.
41. Sayle RA, Milner-White EJ: RASMOL: biomolecular graphics for
all. Trends Biochem Sci 1995, 20:374. 
This program is useful for rendering three-dimensional images of mole-
cules from their molecular coordinates.
6 Genome Biology Vol 3 No 1 George
